SCHEMBL13348488

SCHEMBL13348488

CCc1cnc(-c2cc3c(C)ccc(N(C)S(=O)(=O)c4cccs4)c3[nH]2)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KMT2A Q03164 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 3/20 0.33
MAPT P10636 5/20 0.33
LMNA P02545 4/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
OXTR P30559 1/20 0.32
TDP1 Q9NUW8 3/20 0.32
USP2 O75604 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
HSD17B10 Q99714 1/20 0.32
L3MBTL1 Q9Y468 3/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660296 0.93 ALDH1A1 (0.36) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL1653719 0.92 ALDH1A1 (0.38) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL13348338 0.90 MAPT (0.34) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL2968702 0.84 MAPT (0.35) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL2971603 0.83 ALDH1A1 (0.43) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL1653362 0.83 ALDH1A1 (0.35) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL1653380 0.83 NPC1 (0.35) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL1653240 0.83 ALDH1A1 (0.35) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL2661344 0.83 KMT2A (0.36) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR
SCHEMBL1654798 0.80 ALDH1A1 (0.34) ALDH1A1HPGDSMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144702-A1 INDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-10 US disclosed
US-7652133-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-26 US disclosed
US-20090286975-A1 Indole compound YASUMA TSUNEO 2009-11-19 US disclosed
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144702-A1 INDOLE COMPOUND GCKR, GPR119, SLC5A1 ALDH1A1 376/4885HPGD 1786/4885SMN1; SMN2 4708/4885
US-20090286975-A1 Indole compound GCKR, GPR119, SLC5A1 ALDH1A1 376/4885HPGD 1786/4885SMN1; SMN2 4708/4885
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example GCKR, GCK, KHK ALDH1A1 296/4885HPGD 1947/4885SMN1; SMN2 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.